Quratis Inc. (KOSDAQ:348080)

South Korea · Delayed Price · Currency is KRW

3,575.00

+275.00 (8.33%)

At close: Nov 6, 2026

Market Cap	41.93B -34.8%
Revenue (ttm)	1.10B -41.1%
Net Income	-23.90B
EPS	-254.56
Shares Out	11.73M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,330
Open	3,150.00
Previous Close	3,300.00
Day's Range	2,960.00 - 3,690.00
52-Week Range	1,765.00 - 13,365.00
Beta	-0.28
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Quratis

Quratis Inc. engages in developing vaccines in South Korea. It is involved in developing QTP101, a vaccine for tuberculosis; QTP104, a next-generation mRNA vaccine; CPP (Cell Penetrating Peptide) Platform, a cell and bacterial penetration peptide drug delivery platform technology; and Peptide Nucleic Acid (PNA), a synthetic analogue of DNA in which the deoxyribose phosphate backbone. The company also offers drugs contract development and manufacturing services. Quratis Inc. was incorporated in 2016 and is based in Cheongju-si, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2016

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 348080

Full Company Profile

Financial Performance

In 2025, Quratis's revenue was 2.46 billion, an increase of 557.29% compared to the previous year's 373.80 million. Losses were -29.67 billion, 13.0% more than in 2024.

Financial Statements